OpenLobby.EU
Explore

GSK

GSK

GSK is a global biopharmaceutical company focusing on vaccines and specialty medicines.

Lobbying Activity

Meeting with Olivér Várhelyi (Commissioner) and

1 Dec 2025 · Digital and AI as an enabler in healthcare

Meeting with Stine Bosse (Member of the European Parliament)

7 Nov 2025 · Antimicrobial resistance policy

Meeting with Liesbet Sommen (Member of the European Parliament) and Bayer AG and

23 Oct 2025 · Pharmaceutical legislation + Critical Medicines Act

Meeting with Billy Kelleher (Member of the European Parliament)

16 Oct 2025 · Pharmaceutical Issues

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur)

13 Oct 2025 · Pharma Regulation - Incentives for Antimicrobials

Meeting with Olivér Várhelyi (Commissioner) and

11 Sept 2025 · Consumer protection dimension of specific dossiers

Meeting with Hildegard Bentele (Member of the European Parliament)

3 Sept 2025 · Biotech

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur)

17 Jul 2025 · Pharma Package

Meeting with Alessandra Moretti (Member of the European Parliament)

11 Jun 2025 · public health

GSK urges health-specific focus and streamlined rules for biotech

10 Jun 2025
Topic — The EU consultation proposes measures to accelerate the transition of biotechnology applications.
Message — GSK requests a tailored approach to healthcare biotechnology and the streamlining of clinical trial approvals. They also seek stronger intellectual property protections and safeguards for sensitive trade data.123
Why — Streamlined approvals and stronger data protections would reduce research risks and operational costs.45
Impact — Environmental protection standards could be weakened by efforts to reduce regulatory impacts on production.6
Read full response

Meeting with Hadja Lahbib (Commissioner) and

23 May 2025 · Working visit to GSK vaccine production site.

Meeting with Florika Fink-Hooijer (Director-General Health Emergency Preparedness and Response Authority)

23 May 2025 · Working visit to GSK vaccine production site

GSK urges EU to simplify regulations for life sciences innovation

16 Apr 2025
Topic — This consultation aims to boost EU life sciences competitiveness and reduce global dependencies.
Message — GSK advocates for regulatory harmonisation and a new Office for Life Sciences. They request stronger intellectual property standards and research AI exemptions.123
Why — These changes would protect proprietary data while reducing regulatory delays and costs.45
Impact — Environmental groups may see lower safety standards if chemical and environmental regulations are reduced.6
Read full response

Meeting with András Tivadar Kulja (Member of the European Parliament)

7 Apr 2025 · Critical Medicines Act, prevention, and EU related files.

Meeting with Ingeborg Ter Laak (Member of the European Parliament)

20 Mar 2025 · Medicine shortages, critical medicines act

Meeting with Stine Bosse (Member of the European Parliament)

7 Mar 2025 · European health policy

Meeting with Tomislav Sokol (Member of the European Parliament) and MEDICINES FOR EUROPE and

28 Jan 2025 · Health Policy

Meeting with Peter Van Kemseke (Cabinet of President Ursula von der Leyen)

10 Oct 2024 · EB Summit

Meeting with Estelle Ceulemans (Member of the European Parliament)

25 Sept 2024 · Dossier SANT à venir

Meeting with Dimitris Tsiodras (Member of the European Parliament)

25 Sept 2024 · Public health

Meeting with Oliver Schenk (Member of the European Parliament) and Bundesärztekammer

25 Sept 2024 · Priorities for the next legislative term

Meeting with Stine Bosse (Member of the European Parliament, Committee chair)

20 Sept 2024 · European health policy

Meeting with Tiemo Wölken (Member of the European Parliament)

19 Sept 2024 · Generel exchange (staff level)

Meeting with César Luena (Member of the European Parliament)

19 Sept 2024 · Global health

Meeting with András Tivadar Kulja (Member of the European Parliament) and ViiV Healthcare Limited

18 Sept 2024 · Vaccination

Meeting with Nicolás González Casares (Member of the European Parliament) and RPP Group and ViiV Healthcare Limited

18 Sept 2024 · Non-communicable diseases

Meeting with Laurent Castillo (Member of the European Parliament)

17 Sept 2024 · Europe de la Santé

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur)

12 Sept 2024 · New EU Pharmaceutical Legislation

Meeting with Pietro Fiocchi (Member of the European Parliament)

11 Sept 2024 · Pharmaceutical

Meeting with Tomislav Sokol (Member of the European Parliament)

5 Sept 2024 · Health policy

Meeting with Pernille Weiss-Ehler (Member of the European Parliament)

28 May 2024 · General discussion

GSK urges greater industry participation in EU health assessments

2 Apr 2024
Topic — Rules for conducting joint clinical assessments of medicinal products across the EU.
Message — GSK wants developers to help define the assessment scope and receive longer data submission deadlines. They also demand more time to review reports and protect confidential trade secrets.123
Why — This prevents the accidental release of secrets and allows more time for data preparation.45
Impact — National health systems may experience slower assessments, delaying reimbursement decisions for new medicines.6
Read full response

Meeting with Matthias Ecke (Member of the European Parliament) and European Federation of Pharmaceutical Industries and Associations

28 Mar 2024 · Pharmapaket

Meeting with Ondřej Knotek (Member of the European Parliament)

8 Mar 2024 · Pharmaceutical package

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

5 Mar 2024 · Directive on Medicinal products for human use

Meeting with Alessandra Moretti (Member of the European Parliament)

19 Feb 2024 · Pharma legislation

Meeting with Nathalie Colin-Oesterlé (Member of the European Parliament) and Haleon

19 Feb 2024 · Législation pharmaceutique

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur)

7 Feb 2024 · Pharmaceutical legislation

Meeting with Dolors Montserrat (Member of the European Parliament)

5 Feb 2024 · Revision of the pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

15 Jan 2024 · Directive on Medicinal products for human use

Meeting with Ondřej Knotek (Member of the European Parliament)

11 Jan 2024 · Pharmaceutical package

Meeting with Frédérique Ries (Member of the European Parliament, Shadow rapporteur)

6 Dec 2023 · Revision of the Pharmaceutical Legislation

Meeting with Frédérique Ries (Member of the European Parliament, Shadow rapporteur)

9 Nov 2023 · Revision of the Pharmaceutical Legislation

GSK warns EU pharma reforms threaten innovation and investment

7 Nov 2023
Topic — Revision of EU pharmaceutical legislation to improve access to affordable medicines.
Message — GSK requests maintaining current regulatory data protection periods and removing access conditionalities from innovation incentives. They argue the proposed reductions would harm Europe's competitiveness and patient access to new treatments.123
Why — This would preserve their intellectual property protection periods and avoid penalties for access delays beyond their control.456
Impact — Patients and healthcare systems lose faster access to affordable generic and biosimilar medicines.7
Read full response

GSK warns EU pharmaceutical reform could harm innovation and access

7 Nov 2023
Topic — Revision of EU pharmaceutical legislation to improve medicine access and foster innovation.
Message — GSK requests maintaining current regulatory data protection levels and removing access-based conditions on innovation incentives. They argue linking incentives to access conditions outside manufacturer control is impracticable and could harm European competitiveness.123
Why — This would protect their investment returns and maintain Europe's attractiveness for life sciences investment.45
Read full response

Meeting with Erik Poulsen (Member of the European Parliament) and European Federation of Pharmaceutical Industries and Associations and AbbVie

30 Oct 2023 · Pharmaceuticals legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and MEDICINES FOR EUROPE

27 Oct 2023 · Directive on Medicinal products for human use

Meeting with Sara Cerdas (Member of the European Parliament, Shadow rapporteur)

25 Oct 2023 · EHDS and Pharma

Meeting with Dolors Montserrat (Member of the European Parliament)

19 Oct 2023 · Revision of the pharmaceutical legislation

Meeting with Billy Kelleher (Member of the European Parliament)

11 Oct 2023 · Anti-Microbrial Resistance

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

11 Sept 2023 · Directive on Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

22 May 2023 · Directive on Medicinal products for human use

Meeting with Erik Poulsen (Member of the European Parliament)

17 May 2023 · Pharmaceuticals legislation

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

16 May 2023 · Advanced therapies

Meeting with Tiemo Wölken (Member of the European Parliament) and MEDICINES FOR EUROPE

3 Apr 2023 · EU-Health Policy (staff level)

Meeting with Sara Cerdas (Member of the European Parliament)

27 Mar 2023 · Burden of respiratory infections in the EU

Meeting with Dominique Riquet (Member of the European Parliament)

23 Mar 2023 · Politique de santé

Meeting with Frédérique Ries (Member of the European Parliament)

7 Mar 2023 · Union européenne de la Santé

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur)

26 Jan 2023 · Lessons learned on impact of COVID-19 pandemic

Meeting with Sara Cerdas (Member of the European Parliament, Shadow rapporteur) and European Patients' Forum (EPF)

5 Dec 2022 · Espaço Europeu de Dados de Saúde

GSK urges IP protections in European Health Data Space

28 Jul 2022
Topic — The proposal establishes a framework for sharing health data for research and innovation.
Message — GSK requests clear protections for intellectual property and trade secrets. They propose streamlined data access processes and industry representation on the EHDS Board.123
Why — Stronger intellectual property safeguards protect the company's massive annual research and development investment.45
Read full response

GSK urges F-gas phase-down safeguards to protect medicine supply

29 Jun 2022
Topic — Update of EU rules to reduce emissions from fluorinated greenhouse gases.
Message — GSK requests that the EU ringfence F-gas quotas for medical use and monitor transition progress to ensure patient access. They also advocate for accelerated regulatory pathways for new, lower-emission inhaler propellants.123
Why — This would protect GSK's competitive edge as a major European inhaler manufacturer.45
Impact — Patients with respiratory conditions could lose access to life-saving rescue inhalers.67
Read full response

GSK urges EU to simplify unitary patent certificate procedures

4 Apr 2022
Topic — Creating a unified system for extending patent protections for medicines and agrochemicals.
Message — GSK supports a unitary certificate for new patents and a centralized process for traditional ones. They believe this harmonizes procedures and ensures consistent application. They oppose modifying existing regulations to prevent legal uncertainty.12
Why — This system would lower administrative burdens and provide predictable returns on pharmaceutical research.3
Read full response

GSK urges market incentives and vaccines to combat antimicrobial resistance

23 Mar 2022
Topic — EU proposal for strengthened coordinated One Health actions against antimicrobial resistance.
Message — GSK requests governments establish market-based solutions including transferable exclusivity extensions for new antibiotics, reform health technology assessment processes to recognize antibiotic value, and integrate vaccination programmes into national AMR action plans. They advocate for economic incentives that provide returns while maintaining low prescription volumes and subscription-based reimbursement models.1234
Why — This would provide financial returns for their antibiotic and vaccine development while protecting patent exclusivity on other products.567
Impact — Generic medicine producers lose as patent extensions delay affordable antibiotic access and competition.8
Read full response

Meeting with Cyrus Engerer (Member of the European Parliament)

7 Sept 2021 · Pharmaceutical Strategy

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

28 Apr 2021 · EU vaccine production and pandemic preparedness

GSK Urges EU to Protect Innovation Incentives in Pharma Reform

27 Apr 2021
Topic — Revision of EU pharmaceutical legislation to improve access and foster innovation.
Message — GSK requests a world-class regulatory framework adapted to innovations like AI and advanced therapies, with expedited approval pathways. They want incentives stabilized and not reduced or linked to new obligations, warning this would undermine innovation.12
Why — This would protect their return on high-risk drug development investments and reduce regulatory burden.34
Impact — Patients in countries with access inequalities may wait longer for affordable medicines.5
Read full response

Response to European Health Emergency Response Authority

24 Feb 2021

As a global, science-led healthcare company with a commitment to innovation to help prevent and treat infectious diseases, GSK welcomes the Commission’s vision to strengthen the EU’s pandemic preparedness and response to serious health threats like emerging viruses and drug-resistant bacteria. GSK has an established network of 14 manufacturing and four R&D facilities across the EU, including our global vaccines headquarters, which we are interested to build upon to strengthen pandemic preparedness partnerships in Europe and globally. GSK supports the ambition of an end-to-end Authority and a streamlined approach outlined in policy option 3; however, a centralised structure should not slow down decision-making. Agility, speed, flexibility and collaboration are key success factors. We believe that HERA should: 1. Have meaningful investment to match its ambition 2. Enable a coordinated and global response 3. Simplify pandemic partnerships, protocols, and pathways Meaningful investment to match HERA’s ambition Given its mandate and ambition for end-to-end support, HERA’s funding should match its scope. HERA should be designed to fund and execute projects (e.g. R&D, clinical development) with single entities, and it should be staffed with research, industry and regulatory experts. Manufacturing capacity is a critical missing element of an end-to-end approach. As suggested by the HERA incubator proposal, HERA should connect and enable a manufacturing network of European public and private manufacturing entities, readily able to convert to pandemic activities when needed. While the IIA rightly addresses manufacturing, we believe more emphasis is needed on research & innovation (R&I), including on addressing gaps in funding and incentive mechanisms. HERA brings a unique opportunity to foster a longer-term pipeline of innovative interventions to prevent and mitigate pandemics by enabling discovery, early- and late-stage R&I. Importantly, manufacturers should retain flexibility to choose between the various instruments in the European R&I ecosystem (Horizon, IHI, etc.) that best fits their research needs and objectives. Enable a coordinated and equitable global response HERA presents an opportunity to pull together the robust capabilities of member states and the EU in an aligned and coordinated way. Europe needs to continuously invest in public health infrastructure and policy, with an emphasis on prevention. Together, with properly pooled and significant investment, Europe can support both this region and the world when the next pandemic comes. HERA should be designed to collaborate with global pandemic preparedness institutions, like BARDA and CEPI, to ensure a coordinated and equitable global response. For example, HERA could contribute diagnostics and surveillance tools to strengthen epidemic monitoring and data collection in Europe and globally. Simplify pandemic partnerships, protocols, and pathways Speed, agility, coordination and collaboration are needed for a successful and timely pandemic response. HERA should facilitate alignment and simplification on areas like regulatory pathways, disease containment protocols and movement of goods, including R&D inputs and pandemic response products. Maintaining uninterrupted supply chains is vital to ensure a steady flow of emergency vaccines and other life-saving biopharmaceutical products in Europe and worldwide. We encourage a thoughtful policy response to prevent disruptions to global supply chain integrity. We remain committed to working with the European Commission and all relevant stakeholders to help shape HERA to better protect Europe from future pandemics.
Read full response

Meeting with Sandra Gallina (Director-General Health and Food Safety)

11 Feb 2021 · vaccines

Response to Intellectual Property Action Plan

13 Aug 2020

GSK welcomes the publication of the Intellectual property (IP) action plan roadmap and the recognition of the fundamental role that innovation and intangible assets have in today’s economy and to meet the needs of patients, society and healthcare systems. The EU’s industrial strategy makes clear that innovation is a key contributor to Europe’s long-term industrial success and global competitiveness, and it will be crucial for the EU’s economic recovery from the COVID-19 crisis. Global competition to attract investment in innovative sectors such as pharmaceuticals, however, is increasing. To achieve its industrial ambitions, therefore, the EU must assume a leadership position in driving innovation including maintaining its strong framework of IP rights. As part of its trade strategy, the EU should also promote high standards of IP protection and enforcement globally for the benefit of European innovators. The roadmap also correctly notes how the COVID-19 crisis has illustrated the EU’s dependence on critical technologies, particularly in the health sector. Delivering new medicines to patients, healthcare systems and society is a long, complex, risky and costly process undertaken mostly by industry where IP remains foundational in providing a predictable operating environment conducive to such high-risk investment. This system of innovation, underpinned by a robust patent and IP framework, has led to medical breakthroughs and has built, over many decades, the current base of knowledge, research and manufacturing capacity that ultimately will lead to answers for future health challenges, including the treatment and prevention of COVID-19. GSK supports initiatives to ensure the IP framework is well-calibrated and modern in practice. We call for concrete actions to improve the European innovation and healthcare ecosystem for the benefit of patients and society; including: A less fragmented SPC framework We support the intention to reduce fragmentation in the SPC framework with the creation of a unitary SPC title, enforceable in the whole EU territory. This could simplify the application procedure, reduce duplication and facilitate a consistent application of the SPC Regulation across the EU. As the timeline for the Unitary Patent system remains unknown, we support intermediate solutions such as a “single application portal and a unified grant mechanism” as proposed by EFPIA. An IP framework that supports the discovery and development of antibiotics Given the particular challenges associated with the antibiotic economic model, we support the development of a robust IP incentive system at EU level to reward the successful delivery of innovative solutions against the growing threat of antimicrobial resistance and to ensure a sustainable investment, across the full product cycle, into new antimicrobials targeting resistant pathogens. IP policies that embrace the digital transformation in healthcare We are approaching a revolution in the way we discover treatments, based on a new understanding of genomic data, powered by cutting-edge technology such as artificial intelligence (AI). Thus, IP policies may need to be adapted to support AI-driven innovation. In doing so, we encourage the EU to consider the inputs and findings of WIPO’s work on ‘AI and IP’. Finally, GSK would like to reiterate the importance of the IP action plan in ensuring consistency and alignment between the upcoming pharmaceutical strategy and the industrial strategy, to which it is linked. GSK stands ready to work with the EU Institutions, Member States and all other stakeholders towards creating a bright, competitive and healthy future for Europe.
Read full response

GSK urges EU to prioritize innovation in pharmaceutical strategy

6 Jul 2020
Topic — The EU is consulting on strategies for affordable medicines and pharmaceutical industry innovation.
Message — GSK requests a stable regulatory framework that ensures predictability for research and development. They suggest using real-world evidence and digital tools to accelerate medicine approvals.12
Why — Stronger intellectual property frameworks and new incentives would protect their long-term R&D investments.3
Impact — Public health budgets may face higher costs if vaccine value rewards increase.4
Read full response

Meeting with Annika Nowak (Cabinet of Commissioner Vytenis Andriukaitis)

31 May 2018 · Brexit preparedness

Meeting with Leila Fernandez-Stembridge (Cabinet of Commissioner Pierre Moscovici)

23 Mar 2018 · IP regime generic manufacturers in the pharmaceutical industry

Meeting with Maria Asenius (Cabinet of Vice-President Cecilia Malmström), Nele Eichhorn (Cabinet of Vice-President Cecilia Malmström)

1 Dec 2017 · FTA implementation & transparency / trade relations with China, Turkey, Russia / importance of including vaccines in trade negotiations

Meeting with Marika Lautso-Mousnier (Cabinet of Vice-President Jyrki Katainen)

9 Nov 2017 · Innovation in the pharmaceutical sector, SPC, health technology assessments

Meeting with Carlos Moedas (Commissioner)

26 Jun 2017 · Antimicrobial resistance (AMR)

Meeting with Paula Duarte Gaspar (Cabinet of Commissioner Vytenis Andriukaitis)

30 Sept 2015 · Vaccination

Meeting with Carlos Moedas (Commissioner)

24 Sept 2015 · Challenges of the pharma industry

Meeting with Cecile Billaux (Cabinet of Vice-President Cecilia Malmström)

18 May 2015 · Access to medicines in Africa

Meeting with Věra Jourová (Commissioner) and Microsoft Corporation and

16 Jan 2015 · Round Table on Gender Diversity

Meeting with Aura Salla (Cabinet of Vice-President Jyrki Katainen), Heidi Jern (Cabinet of Vice-President Jyrki Katainen)

5 Dec 2014 · Life sciences contribution to growth and jobs